Special Report: Skin Elements has appointed a major medical supplies distributor to drive sales of its lead disinfectant product, found to be effective against COVID-19.  

As COVID-19 cases continue to rise rapidly around Australia, Skin Elements (ASX:SKN) has entered a deal with Pacific Health Care to distribute its hospital-grade disinfectant product

Invisi Shield SuprCuvr in Australia and New Zealand.

The 12-month agreement represents the next step in commercialisation of its lead product SuprCuvr, found to be highly effective against COVID-19. The deal enables Skin Elements to leverage off Pacific Health’s existing distribution networks.

Skin Elements forecasts the deal will immediately drive sales in the Australian and New Zealand markets and underpin plans to further execute its global commercialisation strategy.

The agreement will be extended up to four years subject to minimum sales volumes of SuprCuvr each year, starting with 1.2 million litres in year one rising steadily with total anticipated volumes of 5.57 million over duration of the agreement.

 

Broad customer base

Pacific Health Care was established in 1987 and has a successful track record of selling and distributing consumable medical products into the Australian medical industry.

Its customers include state governments, major hospitals, clinics, aged care facilities, general practitioners, dentists, surgical and medical sub-distributors along with veterinary clinics and at home patients.

Pacific Health is also quality certified with established distribution centres in Perth, has a national logistics capability and employs registered nurses in its sales representative team.

Skin Elements will supply SuprCuvr to Pacific Health in ready-to-use 80ml, 145ml, 285ml and 565ml spray bottles along with 5 litre and 20 litre refill bulk containers.

Pacific Health has agreed to take responsibility for marketing, sale, supply, and distribution of SuprCuvr to all its current and potential customers in Australia and New Zealand.

 

TGA approval

Skin Elements secured a Therapeutic Goods Administration (TGA) registration for its SuprCuv as a hospital-grade disinfectant product.

The registration was crucial to the commercialisation of SuprCuvr for use in hospitals and aged-care homes — places that are restricted to using only TGA registered disinfectants.

The product has previously been confirmed by independent laboratory testing to have a 99.99999% effectiveness against COVID-19.

Research by Skin Elements indicates the product is the first and only approved disinfectant globally with a 99.99999% efficacy against COVID-19.

 

A ‘significant step forward’

Skin Elements executive chairman Peter Malone said the appointment of Pacific Health Care to distribute SuprCuvr was a key milestone in its commercialisation of the product.  

“This is another significant step forward for the product which will now facilitate the ramp-up of production to meet future growth,” Malone said.

Pacific Health Care CEO Xerxes Surty said the company was excited to be appointed the exclusive distributor for the product.

“SuprCuvr fits immediately into our suite of healthcare and medical products, and we have already placed a significant initial order for immediate delivery into our existing sales channels.”

This article was developed in collaboration with Skin Elements, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.